ORIC-101

DRUG4 trials

Sponsors

ORIC Pharmaceuticals

Conditions

Healthy VolunteersProstatic NeoplasmsSolid Tumor

Phase 1

Study of ORIC-101 in Healthy Adult Subjects

CompletedNCT03324555

ORIC PharmaceuticalsHealthy Volunteers

Start: 2017-10-19End: 2017-12-18Updated: 2018-04-05

Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects

CompletedNCT03835637

ORIC PharmaceuticalsHealthy Volunteers

Start: 2018-03-23End: 2018-07-04Updated: 2019-02-08

Study of ORIC-101 in Combination With Anticancer Therapy

TerminatedNCT03928314

ORIC PharmaceuticalsSolid Tumor

Start: 2019-05-02End: 2023-12-04Updated: 2023-12-15

Study of ORIC-101 in Combination With Enzalutamide

TerminatedNCT04033328

ORIC PharmaceuticalsProstatic Neoplasms

Start: 2019-10-28End: 2023-12-04Updated: 2023-12-15

Related Papers

ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors

Cancer Research Communications2024-08-23

Abstract P015: Biomarker results supporting selection of RP2D from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide

Molecular Cancer Therapeutics2021-12-011 citations

Abstract P041: Initial results from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide in patients with metastatic prostate cancer

Molecular Cancer Therapeutics2021-12-01

Abstract 1420: GR antagonist ORIC-101 overcomes GR-mediated resistance to the combination of AR and AKT inhibition in preclinical prostate cancer cell lines

Cancer Research2021-07-01

Biomarker results supporting selection of RP2D from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel in patients with advanced solid tumors.

Journal of Clinical Oncology2021-05-202 citations

Initial results from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel in patients with advanced solid tumors.

Journal of Clinical Oncology2021-05-202 citations

Abstract 4120: ORIC-101 comprehensively inhibits glucocorticoid pathways to overcome therapeutic resistance in pan-cancer models

Cancer Research2020-08-151 citations

Abstract 4123: ORIC-101 overcomes glucocorticoid receptor-mediated chemoresistance in pancreatic cancer models

Cancer Research2020-08-15

An open-label phase Ib study of ORIC-101 in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide.

Journal of Clinical Oncology2020-02-191 citations